What is the recommended approach to managing ventricular tachycardia, including assessment of hemodynamic stability, immediate synchronized cardioversion, antiarrhythmic drug selection (e.g., amiodarone, procainamide, lidocaine), electrolyte correction, beta‑blocker use, and indications for implantable cardioverter‑defibrillator placement?

Approach to Ventricular Tachycardia

Immediate synchronized cardioversion is mandatory for any patient with hemodynamically unstable VT, defined by systolic blood pressure <90 mmHg, pulmonary edema, or ongoing chest pain; for stable monomorphic VT, intravenous procainamide is the first-line pharmacologic agent, while polymorphic VT requires immediate cardioversion if unstable or intravenous beta-blockers if stable and ischemia-related. 1, 2

Initial Assessment: Hemodynamic Stability

The first critical decision point is determining hemodynamic stability. Unstable VT is defined by:

• Systolic blood pressure <90 mmHg 2
• Pulmonary edema 2
• Ongoing chest pain or angina 2

Always presume wide-QRS tachycardia to be VT when the diagnosis is uncertain 1—this is a Class I recommendation that prevents the potentially fatal error of treating VT with calcium-channel blockers, which can precipitate hemodynamic collapse and ventricular fibrillation 1, 2.

Management of Hemodynamically Unstable VT

Direct-current cardioversion with appropriate sedation is the immediate treatment 1—this is a Class I recommendation that supersedes all pharmacologic options. The electrical therapy algorithm is:

• Monomorphic VT >150 bpm: Start with 100 J synchronized shock; escalate to 200–300 J, then 360 J as needed 2
• Polymorphic VT resembling VF: Deliver unsynchronized 200 J shock immediately 2

Electrical cardioversion is superior to pharmacologic therapy in unstable patients because it provides rapid rhythm restoration while avoiding drug-related complications 2. Do not delay cardioversion to attempt medication trials 2.

Pharmacologic Management of Stable Monomorphic VT

First-Line Agent: Procainamide

Intravenous procainamide is the preferred first-line agent for stable monomorphic VT 1, 2—this carries a Class IIa recommendation from ACC/AHA guidelines. The dosing regimen is:

• Loading: Up to 12–17 mg/kg (typically 50–100 mg/min) 2
• Maintenance: 1–4 mg/min 2
• Stop infusion if: Hypotension develops or QRS widens >50% 2

Procainamide demonstrates higher conversion rates than lidocaine in comparative studies 2, 3 and is more appropriate when early slowing and termination of monomorphic VT are desired 1. Continuous monitoring of blood pressure and QRS duration is mandatory 1, 2. Dose reduction is required in renal dysfunction 2.

Alternative Agents

Amiodarone is a reasonable alternative when procainamide is unavailable or contraindicated:

• Initial: 150 mg IV over 10 minutes 1, 4
• Maintenance: 1 mg/min for 6 hours, then 0.5 mg/min 1, 4
• Class IIb recommendation for stable VT; Class IIa for unstable VT refractory to cardioversion 1
• Preferred in patients with heart failure or acute MI 1, 2
• Less effective for immediate conversion but useful for preventing recurrence 1, 2

Lidocaine has limited utility:

• Bolus: 1.0–1.5 mg/kg, with supplemental 0.5–0.75 mg/kg doses up to total 3 mg/kg 2
• Maintenance: 2–4 mg/min 2
• Class IIb recommendation—only for VT specifically associated with acute myocardial ischemia/infarction 1, 2
• Reduce dose in elderly patients, heart failure, or hepatic impairment 2, 5
• Provides moderate efficacy compared with procainamide 2, 3

Recent evidence from in-hospital cardiac arrest suggests lidocaine may be associated with better outcomes than amiodarone (higher ROSC, 24-hour survival, and favorable neurologic outcome) 6, though this conflicts with the lower guideline recommendation for stable VT.

Management of Polymorphic VT

Normal QT Interval (Ischemia-Related)

• Immediate cardioversion if unstable 1—Class I recommendation
• Intravenous beta-blockers are first-line for recurrent episodes 1—Class I recommendation that improves mortality in acute MI setting
• Intravenous amiodarone may be used for recurrent polymorphic VT when QT is not prolonged 1—Class I recommendation
• Urgent coronary angiography with revascularization is recommended 1 to address the ischemic substrate

Torsades de Pointes (Prolonged QT)

Withdraw all QT-prolonging drugs and correct electrolyte abnormalities immediately 1—Class I, Level of Evidence A.

Specific therapies:

• Intravenous magnesium sulfate: 8 mmol bolus followed by 2.5 mmol/h infusion, even if serum magnesium is normal 1, 2—Class IIa recommendation
• Potassium repletion to 4.5–5 mM/L 1—Class IIb recommendation
• Acute and long-term pacing for torsades due to heart block and symptomatic bradycardia 1—Class I recommendation
• Isoproterenol as temporary treatment for recurrent pause-dependent torsades (not in congenital LQTS) 1—Class IIa recommendation

Contraindicated Therapies

Calcium-channel blockers (verapamil, diltiazem) must never be used for wide-QRS tachycardia of unknown origin 1—this is a Class III (Harm) recommendation, especially in patients with myocardial dysfunction. These agents can precipitate hemodynamic collapse 2.

Refractory or Recurrent VT

When VT is refractory to cardioversion or recurs despite medication:

• Transvenous catheter pace termination 1, 2—Class IIa recommendation
• Urgent catheter ablation for incessant VT 1, 2—Class IIa recommendation
• Intravenous beta-blockers are the single most effective therapy for VT storm 1
• Aggressive ischemia reduction including intra-aortic balloon pump or emergency revascularization for ischemia-driven polymorphic VT 1, 2

Electrolyte Correction and Adjunctive Measures

Correct underlying electrolyte disturbances (hypokalemia, hypomagnesemia) and treat residual ischemia 1, 2—these are Class I recommendations. Electrolyte abnormalities are particularly important in torsades de pointes 1.

Beta-blocker use:

• Essential for polymorphic VT with suspected ischemia 1—Class I recommendation
• Most effective single therapy for VT storm 1
• Reasonable for repetitive monomorphic VT in coronary disease 1—Class IIa recommendation

Post-Conversion Care

After successful VT termination:

• Continuous ECG monitoring is essential 2 to detect premature complexes that may trigger recurrence
• Consider short-term antiarrhythmic infusion (6–24 hours) to prevent early recurrence 2
• Reassess for ongoing therapy needs and underlying cardiac disease 1, 2

ICD Considerations

ICD placement is indicated for secondary prevention in patients with ischemic heart disease who survive sudden cardiac arrest due to VT/VF or experience hemodynamically unstable VT not due to reversible causes, if meaningful survival >1 year is expected 1. This is a Class I, Level of Evidence B-R recommendation.

Common Pitfalls

• Never assume a wide-complex tachycardia is SVT with aberrancy—always treat as VT unless proven otherwise 1, 2
• Do not use adenosine for irregular or polymorphic wide-complex tachycardia 1—it may precipitate atrial fibrillation with rapid ventricular response in pre-excited states
• Monitor blood pressure and QRS duration continuously during procainamide infusion 1, 2 to detect hypotension or excessive QRS widening promptly
• Do not combine multiple antiarrhythmic agents sequentially—if one drug fails, proceed to electrical cardioversion rather than trying another medication 2